基于CAR+FXR双靶点筛选具有“利胆退黄”双重功效的天然活性化合物
批准号:
81960646
项目类别:
地区科学基金项目
资助金额:
33.0 万元
负责人:
魏玉辉
依托单位:
学科分类:
药物设计与药物信息
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
魏玉辉
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
胆汁淤积是临床常见疾病之一,目前治疗胆汁淤积的西药非常缺乏,而中药如茵栀黄方疗效显著。课题组在国家自然科学基金项目(81373927)的研究中发现,茵栀黄方中活性成分京尼平苷可同时激活核受体CAR和FXR,从而调控下游靶基因发挥“利胆退黄”作用,但京尼平苷的代谢物具有一定的肝毒性。如何利用京尼平苷的结构优势同时避免其代谢物毒性发现新的“CAR+FXR”双重激动剂成为本项目的主要研究内容。项目拟在明确京尼平苷与CAR和FXR相互作用模式的基础上,采用“in silico→in vitro→in vivo”层层递进筛选评价策略,通过基于分子对接方法的虚拟筛选,依次在细胞和动物水平上对药效和毒性进行系统评价,以期获得具有“CAR+FXR”双重激动作用的“利胆退黄”双重功效的天然活性化合物。通过本项目的实施,有望发现新型治疗胆汁淤积的先导化合物,同时也为从中药中发现多靶点治疗药物提供一种研究思路。
英文摘要
Cholestasis is one of the common clinical diseases, usually associated jaundice. At present, it is lack of western medicines to treat cholestasis, while traditional Chinese medicine such as Yin-zhi-huang formula has a significant therapeutic effect on cholestasis and jaundice. In our previous researches of the National Natural Science Foundation of China (NSFC: NO.81373927), results showed that geniposide, the active ingredient in Yin-zhi-huang formula, can simultaneously activate the nuclear receptors CAR and FXR, and then regulate the downstream target genes to maintain homeostasis of bile acids and bilirubin. However, genipin, the metabolic product of geniposide in vivo, can lead to hepatotoxicity. How to use the structural advantages and features of geniposide and avoid its metabolite toxicity to discover novel "CAR+FXR" dual agonists has become the main content of this project. On the basis of clarifying the mechanisms of action of geniposide with the double targets CAR and FXR, the "in silico→in vitro→in vivo" cumulative screening evaluation strategy is applied and the virtual screening based on molecular docking method is adopted. Then systematically evaluate the pharmacy effect and toxicity at cellular level in vitro and animals in vivo is used, in order to obtain the natural active compounds with the double effects of normalizing gallbladder to cure jaundice with the simultaneous activation of "CAR + FXR". This project is expected to find new natural lead compounds for the treatment of cholestasis and jaundice, and also provide a new research idea for the discovery of multi-target therapeutic drugs from traditional Chinese medicine.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:--
发表时间:2023
期刊:中国药物警戒
影响因子:--
作者:王晓慧;张帆;夏文彬;魏玉辉
通讯作者:魏玉辉
DOI:10.5246/jcps.2022.08.051
发表时间:2022
期刊:Journal of Chinese Pharmaceutical Sciences
影响因子:--
作者:Zhang Fan;Wang Xiaohui;Saad Abdulaziz Ahmed A;Xi Lili;Ma Xiaohua;Shi Axi;Wei Yuhui
通讯作者:Wei Yuhui
DOI:--
发表时间:2023
期刊:药学学报
影响因子:--
作者:张帆;吕东霞;董毓松;秦佳琪;王国旭;骆洋;饶志;魏玉辉
通讯作者:魏玉辉
DOI:10.3389/fphar.2023.1197856
发表时间:2023
期刊:Frontiers in pharmacology
影响因子:5.6
作者:
通讯作者:
DOI:--
发表时间:2022
期刊:Discovery Medicine
影响因子:1.4
作者:Tiantian Shen;Axi Shi;Yuhui Wei;Xinyi Luo;Lili Xi
通讯作者:Lili Xi
基于PXR/CAR/TNFR1相关通路研究栀子“自解毒”效应的物质基础及其分子机制
- 批准号:82174067
- 项目类别:面上项目
- 资助金额:55.00万元
- 批准年份:2021
- 负责人:魏玉辉
- 依托单位:
国内基金
海外基金















{{item.name}}会员


